APA

Dutton S. J., Ferry D. R., Blazeby J. M., Abbas H., Dahle-Smith A., Mansoor W., Thompson J., Harrison M., Chatterjee A., Falk S., Garcia-Alonso A., Fyfe D. W., Hubner R. A., Gamble T., Peachey L., Davoudianfar M., Pearson S. R., Julier P., Jankowski J., Kerr R. & Petty R. D. (20140909). Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. : The Lancet. Oncology.

Chicago

Dutton Susan J, Ferry David R, Blazeby Jane M, Abbas Haider, Dahle-Smith Asa, Mansoor Wasat, Thompson Joyce, Harrison Mark, Chatterjee Anirban, Falk Stephen, Garcia-Alonso Angel, Fyfe David W, Hubner Richard A, Gamble Tina, Peachey Lynnda, Davoudianfar Mina, Pearson Sarah R, Julier Patrick, Jankowski Janusz, Kerr Rachel and Petty Russell D. 20140909. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. : The Lancet. Oncology.

Harvard

Dutton S. J., Ferry D. R., Blazeby J. M., Abbas H., Dahle-Smith A., Mansoor W., Thompson J., Harrison M., Chatterjee A., Falk S., Garcia-Alonso A., Fyfe D. W., Hubner R. A., Gamble T., Peachey L., Davoudianfar M., Pearson S. R., Julier P., Jankowski J., Kerr R. and Petty R. D. (20140909). Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. : The Lancet. Oncology.

MLA

Dutton Susan J, Ferry David R, Blazeby Jane M, Abbas Haider, Dahle-Smith Asa, Mansoor Wasat, Thompson Joyce, Harrison Mark, Chatterjee Anirban, Falk Stephen, Garcia-Alonso Angel, Fyfe David W, Hubner Richard A, Gamble Tina, Peachey Lynnda, Davoudianfar Mina, Pearson Sarah R, Julier Patrick, Jankowski Janusz, Kerr Rachel and Petty Russell D. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. : The Lancet. Oncology. 20140909.